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Abstract
During development a tightly controlled signaling cascade dictates the differentiation, maturation and survival of
developing neurons. Understanding this signaling mechanism is important for developing therapies for neurodegenerative
illnesses. In previous work we have sought to understand the complex signaling pathways responsible for the development
of midbrain dopamine neurons using a proteomic approach. One protein we have identified as being expressed in
developing midbrain tissue is the vitamin D receptor. Therefore we investigated the effect of the biologically active vitamin
D3 metabolite, calcitriol, on primary fetal ventral mesencephalic cultures of dopamine neurons. We observed a dose
responsive increase in numbers of rat primary dopamine neurons when calcitriol was added to culture media. Western blot
data showed that calcitriol upregulated the expression of glial derived neurotrophic factor (GDNF). Blocking GDNF signaling
could prevent calcitriol’s ability to increase numbers of dopamine neurons. An apoptosis assay and cell birth dating
experiment revealed that calcitriol increases the number of dopamine neurons through neuroprotection and not increased
differentiation. This could have implications for future neuroprotective PD therapies.
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Introduction
Midbrain dopamine (mDA) neurons are of particular impor-
tance owing to their selective degeneration in Parkinson’s disease
(PD). Drug therapy is the most common intervention for PD,
however current therapies only provide effective symptomatic
control for approximately 10 years and do not alter the course of
the illness. For this reason, alternative therapies are required that
can halt the progression of the disease or even reverse the
degenerative process. Future therapies could include neuropro-
tective strategies, to prevent continued degeneration of the nigro-
striatal mDA neurons, or cell replacement therapies using mDA
neurons derived from stem cells. In both cases, understanding key
extracellular signals that increase the development or survival of
mDA neurons may improve the potential of PD therapies.
Neurotrophic factors, such as glial derived neurotrophic factor
(GDNF) [1], brain derived neurotrophic factor (BDNF) [2] and
mesencephalic astrocyte derived neurotrophic factor (MANF) [3]
all confer neuroprotection to midbrain dopamine neurons. GDNF
has long been known to protect dopamine neurons in animal
models of PD [1] and has previously demonstrated restoration of
the nigro-striatal circuit in the brains of MPTP-lesioned monkeys
when delivered by infusion [4] or lentiviral transfection [5].
Indeed, GDNF has been used in clinical trials, with variable
success, showing improvement in PD symptoms in some cases
[6,7], but limited efficacy in others [8]; possibly because the
GDNF was not reaching the target neurons in the substantia nigra
and putamen [8]. Therefore, neuroprotection by neurotrophic
factors is still considered a plausible therapy for PD although
current methods require direct intraparenchymal infusion of these
factors because they are not able to cross the blood brain barrier
(BBB) [6,7]. Proteins or signaling molecules that can pass the BBB
to elevate expression of these neurotrophic factors or to stimulate
neuroprotection themselves are therefore highly desirable.
To identify signaling proteins responsible for specification,
maintenance, axonal guidance and survival of developing mDA
neurons, we have previously performed multiplexed quantitative
proteomic analysis of the developing rat embryonic midbrain [9].
This work identified a number of candidate signaling proteins that
may be involved in the development of midbrain dopamine
neurons. One protein identified in this study was the vitamin D
receptor (VDR). This is a nuclear receptor protein, recognizing the
biologically active metabolite of vitamin D3, calcitriol. It is already
known that vitamin A (retinoic acid) and vitamin C (ascorbic acid)
play major roles in the development of mDA neurons [10,11], so,
in the work presented here we sought to investigate similar
functions for calcitriol.
While vitamin D is most commonly associated with the growth
and remodeling of bone, recent studies have identified a much
broader spectrum of activity along with widespread expression of
the VDR protein in over 36 different cell types [12] including C6
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glioma cells [13] and human glioblastoma cells [14]. Vitamin D3
(calcitriol)’s effects are mediated through binding of this ligand to
its nuclear receptor and formation of heterodimers with the
retinoid receptors, RXR and RAR, and interaction with other
coactivator and corepressor nuclear receptors, which are capable
of initiating expression of over 500 genes [15]. By regulating this
large number of genes and through post-transcriptional modifica-
tion events, calcitriol has been shown to influence cell proliferation
and differentiation[16–19]. Importantly for this study, calcitriol
has also been shown to increase glial-derived neurotrophic factor
(GDNF) expression in the striatum [20] and cortex [21] of adult
rats and may also partially protect against 6-hydroxydopamine
induced lesions [22]. GDNF is a well-known neurotrophic factor
for midbrain dopamine neurons and has been shown to stimulate
differentiation of stem cells towards a dopaminergic cell fate [23].
In animal models of PD, GDNF has also been shown to simulate
sprouting of remaining axons [4,5]. Given these pro-dopaminergic
effects of GDNF and the possible link with calcitriol, we
investigated the effect of calcitriol on cultures of E12 primary rat
ventral mesencephalic (VM) tissue.
The results described in this article show that the vitamin D
receptor protein is expressed in E12 VM tissue and that calcitriol
causes a dose-responsive increase in the number of DA neurons in
primary E12 VM cultures. This increase in DA neurons was
concurrent with a two-fold increase in GDNF expression.
Furthermore, blocking GDNF signaling using heparinase III
demonstrated that the increase in DA neurons was a result of
calcitriol-induced increase in GDNF expression in cultures.
Finally, we show that the increase in DA neurons is due to
reduced neuronal death and not increased differentiation of the
dopaminergic population. Therefore, vitamin D3 and specifically
its active metabolite calcitriol have an important role to play in the
protection of dopamine neurons, with implications for potential
neuroprotective strategies or in neuronal replacement therapies for
PD.
Results
Vitamin D3 Receptor Protein is Expressed in the
Developing Rat Ventral Mesencephalon
We initially identified expression of the VDR protein in the
developing rat ventral mesencephalon from a previous multiplexed
proteomic investigation into developing midbrain tissue [9]. We
profiled proteins expressed in the VM of Sprague-Dawley rats
aged E11 to E14 and VDR was identified by mass spectrometry
from five unique peptides with a confidence interval greater than
99% (Figure 1A). In addition to the identification of the receptor,
we also identified vitamin D binding protein, responsible for
transporting calcitriol to target organs, from 4 unique peptides,
with a confidence interval of 99.9%. Quantitative data obtained
from proteomics suggested there was no difference in the
expression of VDR over the time course of VM development
studied (tissue ages E11– E14; data not shown).
Western blotting of whole tissue lysates obtained from E12
embryos detected a single band at approximately 34 kDa,
corresponding to VDR (Figure 1B). Additionally, 12 mM cryostat
sections obtained from E13 embryos were immunolabeled and
expression of VDR was observed in the dopaminergic region of
the ventral mesencephalon (Figure 1C). Increasing dorso-ventral
expression of VDR was observed, showing highest expression at
the ventral-most edge of the mesencephalon, corresponding to the
dopaminergic region. Monolayer cultures of E12 neurons,
dissociated and cultured for 7 days, were also stained for TH
and VDR (Figure 1D). Of the TH+ neurons, 94% 65.4% co-
expressed VDR.
These results conclusively demonstrated expression of VDR in
the developing midbrain and suggested that vitamin D could play
a signaling role during specification of mDA neurons.
Addition of Calcitriol Increases the Number of Dopamine
Neurons in Primary Cultures of Embryonic Rat VM
We next investigated whether the vitamin D3 metabolite has
any influence on the number of dopamine neurons obtained from
primary neural cultures of E12 rat VM tissue. In all experiments,
calcitriol was used examine the effects of vitamin D3 signaling on
neurons as it is the active metabolite produced from the
biologically inactive vitamin by two oxidation reactions occurring
in the liver and kidneys [12]. To ascertain the optimum
concentration of calcitriol, we used varying concentrations added
to culture media, ranging from physiological levels (estimated at
approximately 100 pM [12]) to 100 nM.
Following seven days of culture, calcitriol elicited a concentra-
tion dependent increase in the percentage of tyrosine hydroxylase
immunoreactive (TH+) neurons (ANOVA (F(5,498) = 13.58,
p,0.0001). At 10 nM calcitriol concentration, the percentage of
TH+ neurons of the whole cell population was increased by almost
two fold compared to control conditions (6.0% 60.7% in control
cultures, vs. 11.5% 61.1% with 10 nM calcitriol, Bonferroni post-
test t = 6.14, p,0.01) (Figure 2 A–C).This was shown to be solely
an effect of calcitriol addition as no significant difference was
observed between control and vehicle only conditions (5.74%
60.5 vs. 4.7% 60.6%, Bonferroni post-test t = 0.86, n.s.). In
cultures exposed to 100 nM calcitriol, the percentage of TH+
neurons was not significantly different to levels obtained under
control conditions. There was no difference in the percentage of b-
III tubulin+ cells between control and 10 nM calcitriol-stimulated
conditions (41.5% 62.4 vs. 36.2% 62.6, unpaired t-test t = 1.49,
n.s.). The ventral midbrain dopaminergic identity of the TH+
neurons was confirmed through co-expression with other DA
markers: aromatic acid decarboxylase (AADC), the nuclear
orphan receptor Nurr1, the dopamine transporter (DAT), and
vesicular monoamine transporter 2 (VMAT2) (Figure 2 D–G).
GDNF Expression is Upregulated by Calcitriol
GNDF is a neurotrophic factor that is known to influence
development and survival of dopamine neurons. As GDNF has
previously been shown to be upregulated in response to calcitriol
stimulation [13,20,21], we used Western blotting to see if
expression of GDNF was also upregulated in our cultures. Primary
E12 VM cultures were cultured either in media containing 10 nM
calcitriol or control media (no calcitriol) for 7 days. Total protein
was extracted from the cultures and transferred to nitrocellulose
membrane for detection with an anti-GDNF antibody. Using
integrated optical density measurements normalized to GAPDH
expression, GDNF expression was increased 1.860.2 fold (n = 7,
unpaired t-test, t = 4.4, p,0.05) in cells treated with 10 nM
calcitriol compared to control cultures (Figure 3A, B).
Increased Numbers of Dopamine Neurons are Directly
Attributable to Calcitriol-induced Increase in GDNF
Expression
GDNF signaling relies on heparin sulphate proteoglycan
binding, and therefore treatment with Heparinase III will inhibit
exogenous GDNF signaling [24,25]. To determine whether or not
GDNF expressed in response to calcitriol is responsible for the
increase in dopamine neurons obtained from E12 VM tissue, we
Calcitriol Protects Dopamine Neurons
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blocked GDNF signaling through the addition of 0.3 U/ml
Heparinase III to cultures.
Blocking GDNF signaling had a significant effect in reducing
the percentage of dopamine neurons in E12 VM cultures
(ANOVA F(3,167) = 22.05, p,0.0001). In cultures without calci-
triol, heparinase III reduced the percentage of dopamine neurons
of the total cell number by approximately three fold in comparison
to control media (2.360.3% in +Hep cultures vs. 6.360.8% in
control cultures, Bonferroni post-test t=3.21, p,0.001)
(Figure 3C). This is likely a result of inhibiting GDNF that is
naturally expressed in cultures. The reduction in DA neurons
increased to five-fold when compared to numbers of DA neurons
observed in cultures containing 10 nM calcitriol but no heparinase
III (2.360.3% in +Hep cultures vs. 11.761.5% in +Calcitriol
cultures, Bonferroni post-test t=7.39, p,0.01).
To see if heparinase III could prevent the effect of calcitriol-
induced increase in DA neurons, we exposed E12 VM cultures to
10 nM calcitriol and 0.3 U/ml heparinase III simultaneously for 7
days. Under these conditions, calcitriol failed to counteract the
effects of heparinase III and there was no difference in the
numbers of DA neurons between cultures treated with calci-
triol+heparinase III and cultures with heparinase III alone
Figure 1. Expression on vitamin D receptor protein. Vitamin D receptor protein was identified in developing ventral midbrain tissue harvested
from embryonic rats. A) Five unique peptides were identified and used to identify VDR. B) VDR protein was also identified by a single band in Western
blots of whole tissue lysate obtained from E12 VM of rats. C) Immunohistochemistry of E13 sagittal sections taken through the midbrain show
overlapping expression of vitamin D receptor (VDR, green) and tyrosine hydroxylase (TH, red). Scale bar: 20 mM. D) Co-expression of VDR and TH was
also observed in single cell cultures of E12 VM tissue. Total cells were labeled with DAPI (blue). Scale bar: 50 mM.
doi:10.1371/journal.pone.0062040.g001
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(2.360.3% vs. 3.260.6%, Bonferroni post-test t=0.75, p = 0.17)
(Figure 3C–E). This suggests that calcitriol is exerting a neuropro-
tective effect through the elevation of GDNF signaling.
Calcitriol Increases Dopamine Neurons in Culture
through a Reduction in Apoptosis
To identify the mechanism by which calcitriol-mediated GDNF
increases the number of dopamine neurons obtained from primary
VM cultures, we performed a caspase assay to identify the number
of apoptotic cells in culture. A pan-caspase kit was used to label
cells at all stages of apoptosis. To highlight the dopamine neuron-
specific effects, the proportion of caspase-positive DA neurons was
normalized against the proportion of caspase-positive cells in the
total cell population (where a ratio of 1.0 indicates that dopamine
neurons are equally as susceptible to cell death as all cells in the
culture). Our data indicates that calcitriol increases the number of
DA neurons in culture through a reduction in apoptosis (ANOVA
F(3,182)=15.04, p,0.0001) (Figure 4 A–E).
In the normalized data we observed a significant decrease in the
amount of apoptotic dopamine neurons when calcitriol was added,
compared to control media (0.9360.06 vs. 0.6560.06, Bonferroni
post-test t=2.12, p,0.05) (Figure 4 A, B, E). However, when
0.3 U heparinase III was added to media, a significant increase in
the ratio of apoptotic dopamine neurons was observed in
comparison to media containing 10 nM calcitriol (1.6160.2 in
+Hep cultures vs. 0.6560.1 in+calcitriol cultures, Bonferroni post-
test t=6.38, p,0.001) (Figure 4 B, C, E). This was partially
reversed in media containing both 0.3 U/ml heparinase III and
10 nM calcitriol (1.2460.1 vs. calcitriol alone, Bonferroni post-test
t=4.34, p,0.001) (Figure 4 D, E). Calcitriol was able to reduce the
proportion of DA neurons undergoing apoptosis in the presence of
heparinase III, (1.2460.1 in +Hep +calcitriol cultures vs.
1.6160.2 in +Hep cultures, p,0.001) (Figure 4 C, D, E).
Calcitriol does not Increase Dopaminergic Differentiation
in Primary Neural Cultures
To confirm whether the increase in dopamine neurons was
a result of neuroprotection or an increase in differentiation of
neural progenitors to a DA neuron phenotype, 10 mM bromo-
deoxyuridine (BrdU) was added to the media during the first three
days of culture. BrdU is a synthetic thymidine analog that is
incorporated into mitotic cells. Cells that had divided in the
presence of BrdU were then identified through antibody staining,
and cells double-labeled with BrdU and TH were classed as DA
neurons that were newly differentiated in culture following
terminal mitotic division. There was no difference in the number
of double-labeled BrdU+/TH+ neurons comparing cultures
containing calcitriol and controls, Figure 4F (24.6% 61.5 vs.
21.7% 64.25, unpaired t test, t=0.63, p = 0.54 ). This demon-
strates that calcitriol has no direct effect on differentiation,
therefore any changes in DA neuron numbers are related to
neuroprotection.
Discussion
Neurotrophic factors play a crucial role in neuroprotection,
both during development and in the adult brain. Using a dose
response assay we have demonstrated that calcitriol can upregulate
GDNF expression in primary neural cultures and increase the
Figure 2. Effect of calcitriol addition to culture media on
dopamine neurons. Dose responsive increase in the number of TH
immunoreactive neurons was obtained with addition of calcitriol to
media. A) primary E12 control cultures and B) cultures with 10 nM
calcitriol showing immunostaining with antibodies specific to tyrosine
hydroxylase (red) and Tuj1 (green) counterstained with DAPI (blue).
Scale bars: 20 mM. C) The percentage of dopamine neurons obtained
from cultures with various concentrations of calcitriol added to media.
Error bars represent SEM, ***p,0.001, **p,0.01, *p,0.05. The
percentage of dopamine neurons obtained from primary E12 ventral
mesencephalic cultures increased when calcitriol was added to media
up to an optimum concentration of 10 nM. Dopamine neurons were
also shown to be immunoreactive for other ventral midbrain DA neuron
marker proteins: (D) aromatic acid decarboxylase (AADC); (E) Nurr1; (F)
dopamine transporter (DAT); and (G) vesicular monoamine transporter
2 (VMAT2). Scale bars: 10 mM.
doi:10.1371/journal.pone.0062040.g002
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numbers of DA neurons obtained. Through GDNF blocking
studies we showed that increases in DA neurons were in response
to increased GDNF signaling and were due to neuroprotection
rather than increased differentiation. Taken together, this data
suggests that calcitriol could be used in future neuroprotective
strategies against the progression of PD.
E12 is a critical time point in the development of mDA neurons.
We have shown here, through a combination of proteomics,
immunohistochemistry and Western blotting that the VDR
protein is expressed in the rat VM specifically at that time,
corroborating previous evidence that the vitamin D receptor is
expressed in the developing rat brain [26]. Importantly, the
vitamin D binding protein, which is responsible for transporting
vitamin D3 and its metabolites to target organs [27], was also
identified by proteomic screening of the developing ventral
mesencephalon [9]. Coupled with the facts that biologically active
forms of vitamin A (retinoic acid) and vitamin C (ascorbic acid)
have already been shown to play a major role in the development
of the midbrain dopamine neurons our data here suggest that
vitamins and their metabolites may have an essential role to play in
the development of the midbrain.
Using a dose response investigation, it was clear that addition of
10 nM calcitriol for a culture period of 7 days significantly
increased the number of dopamine neurons. At this optimum
concentration of calcitriol we observed almost a two fold increase
in the number of TH+ neurons obtained from E12 VM cultures.
Figure 3. Relationship between calcitriol and GDNF signaling. The beneficial effect of calcitriol addition to media was shown to be a result of
increased GDNF. (A, B) 10 nM calcitriol added to media caused almost a 1.8-fold increase in GDNF expression, observed by Western blotting. GAPDH
was used as loading control; lanes:+with calcitriol, - control; *p,0.05. In the presence of 0.3 U heparinase III, the number of dopamine neurons
observed was significantly decreased regardless of calcitriol incorporation (C). Bars represent percentage tyrosine hydroxylase immunoreactive
neurons as a percentage of total cells6SEM. ***p,0.001, **p,0.01. Representative images of primary ventral mesencephalic cultures supplemented
with 0.3 U heparinase III without calcitriol (D) and with the addition of 10 nM calcitriol (E). Cultures were stained with tyrosine hydroxylase (red) and
b-III tubulin (green). Scale bar: 20 mm.
doi:10.1371/journal.pone.0062040.g003
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This represents a considerably higher concentration than the
physiological level of circulating vitamin D3, which is thought to be
in the range of 50–125 pM [12]. It is important to consider
however, that the amount of calcitriol added to cultures may not
accurately reflect the bioavailable calcitriol bound to serum
proteins, therefore a direct comparison between physiological
levels and culture levels may not be appropriate.
In accordance with other studies [13,20,21], we showed that
GDNF protein levels were increased approximately two fold in
response to calcitriol addition. Furthermore, through the addition
of 0.3 U/ml heparinase III to cultures, we demonstrated that the
increase in dopamine neurons was a direct consequence of
elevated GDNF levels. Addition of GDNF to primary dopami-
nergic cultures has been long acknowledged to promote survival of
dopamine neurons and reduce apoptosis [28]. GDNF signaling
requires heparin sulphate glycosaminoglycans [24] and is therefore
greatly attenuated by addition of heparinase III to cultures [25], as
binding of GDNF to heparin is essential to allow the neuropro-
tective effects of GDNF [29].In the absence of GDNF signaling
dopamine neurons became significantly more prone to apoptosis
than the cell population as a whole, as determined by pan caspase
expression. This is in accordance with the known neuroprotective
properties of GDNF on midbrain dopamine neurons.
GDNF has been used in clinical trials of PD in an attempt to
slow dopamine neurodegeneration. Open label trials have shown
benefits of continuous infusion of GDNF into the putamen of PD
patients [6,7], however these have not been supported by double
blind investigations [8,30] and several side effects have been
reported [5]. It has been suggested that direct delivery into the
putamen results in uneven distribution of GDNF resulting in
limited bioavailability [31]. Systemic administration of GDNF is
likely to be unsuccessful owing to the limited penetration into brain
tissue from the blood stream [6]. However, passage of GDNF
through the blood-brain barrier using molecular Trojan horse
technology, did demonstrate protection against a chemically
induced lesion of the nigro-striatal pathway [32]. Small molecules
are able to cross the blood brain barrier, therefore systemically
administered calcitriol may be able provide better neuroprotection
through elevating GDNF expression within the basal ganglia
without the need for intraparenchymal infusion. Importantly,
expression of the vitamin D receptor protein has been described in
the adult human brain, with robust expression observed in the
substantia nigra [33]. Alternatively, direct delivery of calcitriol to
the putamen through continuous perfusion could also be
considered.
It has been postulated that vitamin D deficiency may play a role
in the degeneration of DA neurons in PD patients. There is
evidence to suggest that polymorphisms in the VDR gene confer
susceptibility to PD [34,35]. Additionally, low serum levels of
vitamin D are associated with PD [36,37]. Coupled with the
observation that VDR expression is higher in the substantia nigra
than other brain regions [33], these facts indicate that dopamine
neurons could be more susceptible to alterations in vitamin D
signaling. Seemingly in contradiction to these data, vitamin D
restriction in klotho mice rescues degeneration of the mesencephalic
dopamine neurons. However, this could indicate that klotho mice
are unable to regulate vitamin D signaling normally, leading to
high serum levels which in turn can induce susceptible neurons to
Figure 4. Calcitriol is neuroprotective and does not increase
differentiation. The increase in dopamine neurons obtained from
cultures was shown to be a result of increased neuroprotection
afforded through calcitriol addition, rather than changes in differenti-
ation. (A–D) Immunolabeling with a pan-caspase marker (red) and
antibodies to tyrosine hydroxylase (green) counterstained with DAPI
(blue), for: A) control media, B) 10 nM calcitriol, C) 0.3 U/ml Heparinase
III and D) 10 nM calcitriol with 0.3 U/ml heparinase III. Scale bars: 20 mM.
E) The number of apoptotic dopamine neurons was significantly
increased when heparinase III was added to media. Bars represent the
ratio of caspase+ dopamine neurons to caspase+ DAPI+ cells. Error bars
represent SEM, ***p,0.001, *p,0.05. F) The percentage of TH+ neurons
that had undergone terminal mitotic division and specification during
culture was not significantly different when 10 nM calcitriol was added
to cultures. Bars represent percent BrdU+ dopamine neurons, error bars
are SEM.
doi:10.1371/journal.pone.0062040.g004
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undergo cell death [38]. With these points in mind, any use of
vitamin D as a therapy must be carefully controlled to avoid
excessive serum concentrations. The strong links between vitamin
D signaling and PD however, coupled with our observations of
neuroprotection detailed in this manuscript suggest that a future
therapy focused on the control of vitamin D signaling is
a possibility.
To conclude, this work supports previous evidence that gene
expression can be directly stimulated by small, biologically active
molecules, including vitamins and their metabolites. We have
shown conclusively that the VDR is expressed in developing rat
ventral midbrain. Furthermore, the bioactive vitamin D3 metab-
olite calcitriol can increase the numbers of dopamine neurons
obtained from primary neuronal cultures of the developing ventral
midbrain. This effect is a direct result of upregulation of GDNF
protein levels and subsequent neuroprotection, and not an effect of
increased differentiation. These important findings indicate that
vitamin D3, and its biologically active metabolite calcitriol, could
have important roles to play in future neuroprotective or
neurorestorative PD therapies. To investigate the potential of this
work to the fullest, future studies should concentrate on in vivo
analysis to ascertain whether or not calcitriol, administered
systemically, can improve survival of dopamine neurons in animal
models of PD or in grafted cells.
Materials and Methods
Ethics Statement
All animal experiments were conducted in accordance with the
UK Home Office Animals (Scientific Procedures) Act 1986.
Sprague-Dawley rats used for the study were bred and housed in
a dedicated on-site facility and provided with food and water ad
libitum.
Animals
Time mated dams were sacrificed by cervical dislocation at
embryonic day (E) E12 or E13 (day of plugging designated as E0).
The uterine horns were removed, the embryonic sacs opened and
embryos removed, killed using schedule one methods, and
transferred to ice cold Dulbecco’s modified Eagle’s medium
(DMEM) containing 0.6% glucose, 0.12% sodium bicarbonate,
and 50 mM HEPES buffer. Tissue and dissecting media were
maintained at 4uC to minimize protein degradation.
Proteomic Analysis
The proteomic analysis of tissue has been described in detail in
a previous publication [9]. Briefly, ventral mesencephalic tissue
was obtained from embryonic rats aged E11 to E14 and proteins
extracted. Tryptic peptides were produced by incubation of
reduced and alkylated proteins in trypsin for 24 hours at 37uC.
Peptides were labeled with iTRAQ reagents, combined and
lyophilised. Labeled peptides were dissolved in 2.4 ml of 10 mM
phosphate, 20% acetonitrile and resolved by strong cation
exchange. Resulting fractions were then separated using reverse
phase chromatography and spotted onto target plates for mass
spectrometric analysis. Samples were analyzed by tandem matrix
assisted laser desorption ionization mass spectrometry and proteins
identified using GPS explorer.
Preparation of Embryonic Sections
Embryos were removed as previously described and fixed in 4%
PFA for twelve hours before equilibrating in a 30% sucrose
solution until they sank. Fixed embryos were embedded in OCT
media and frozen sections cut at a thickness of 12 mm using
a cryostat. Serial sections were collected on subbed microscope
slides and allowed to dry.
Primary Neuron Culture
E12 tissue was prepared as described and incubated for 30
minutes in 0.05% DNase, 0.1% trypsin in DMEM. Tissue was
washed in 0.05% DNase and a single cell suspension produced by
gentle trituration using a P200 pipette tip. Cells were pelleted and
re-suspended in primary culture media (Neurobasal (Invitrogen)
containing 1% antibiotic-antimycotic (PAA), 1% v/v B27 (In-
vitrogen), 1 mM L-glutamine (Sigma), 0.45% w/v glucose (Sigma),
1% v/v fetal calf serum (Sigma)). Viable cells were counted using
trypan blue exclusion and a final cell density of 1,000 live cells/mL
produced by dilution in primary culture media. 30,000 cells were
dropped into the center of a poly-d-lysine and laminin coated
coverslip and incubated for 4 hours to allow attachment. Wells
were then flooded with 500 mL of culture media, with addition of
an extra 500 mL every second day. For studies using vitamin D3,
the biologically active metabolite, calcitriol (1,25–dihydroxy
vitamin D3; 1,25(OH)2D3), was added to media. Heparinase III
(R&D Systems) was used to block GDNF signaling [24,25,29] by
adding 0.3 U/ml to culture media. Following seven days of
culture, cells were washed in phosphate buffered saline and fixed
using 4% paraformaldehyde at 4uC for 30 minutes.
For BrdU assays, primary neurons were prepared as described
and cultured in media containing 10 mM BrdU for the first three
days of culture. Media was then removed and cells washed before
adding fresh media without BrdU. Additional media was added
every second day for a total of 7 days culture.
Immunochemistry
Sagittal sections or cultured cells were briefly rinsed in TRIS
buffered saline (TBS) before blocking in TBS containing 5%
normal goat serum for 1 hour. Primary antibodies were diluted in
TBS and applied to slides overnight at room temperature for
sections or 4uC for cells at the following concentrations: rabbit anti
VDR (Abcam) 1:750; mouse anti tyrosine hydroxylase (Chemi-
con); rabbit anti tyrosine hydroxylase (Chemicon) 1:1,000; rabbit
anti GDNF (Abcam) 1:1,000; mouse anti b-III tubulin (Covance)
1:500. Sections or cells were then washed three times for 5 minutes
each in TBS and incubated in fluorescent secondary antibodies
(Cheshire Sciences) for 2 hours at 1:300. Stained samples were
washed three times in TBS for 5 minutes each, before rinsing in
deionized water and cover-slipping using hard set mounting media
containing DAPI (Vector Labs). Images were collected using
a Nikon T80i inverted fluorescent microscope using DAPI, FITC
and TRITC filters fitted with a Hamamatsu Orca imaging system
controlled by NIS Elements.
Western Blotting
For Western blotting of embryonic ventral midbrain, tissue was
dissected out and placed in ice cold lysis buffer (6 M urea, 2 M
thiourea, 4% 3-[(3-Cholamidopropyl) dimethylammonio]-1-pro-
panesulfone (CHAPS), 0.5% sodium dodecyl sulphate (SDS)).
Tissue from all embryos taken from a single dam was pooled
together and broken up by sonication. Samples were stored at
280uC until required. Alternatively, cultured cells were washed
with PBS and detached by addition of trypsin for 1 minute. Cells
were harvested by addition of 10x volume of culture media and
centrifugation at 1200 g for 3 minutes. Cell pellets were re-
suspended in 200 ml of PBS and counted using the trypan blue
exclusion method. Cells were diluted in phosphate buffered saline
(PBS) and 4x SDS loading buffer to give a final density of 250,000
cells per 50 ml. Cell suspensions were sonicated on ice three times
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for 5 seconds with 30 second intervals and stored at 280uC until
used.
25 mg of total protein extract from tissue or 250,000 cells from
culture experiments from each age was loaded into 12.5%
acrylamide gels and resolved at 150 volts for 50 minutes. The
gel was removed from the cassette and briefly rinsed in distilled
water. Semi-dry blotting was used to transfer proteins to
a nitrocellulose membrane over a period of 60 minutes at 10
volts. The membrane was probed with specific antibodies to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Abcam;
1:1,000), VDR (VDR; Abcam; 1:1,000) or glial derived neuro-
trophic factor (GDNF; 1:1,000; Abcam). Membranes were first
blocked using 5% bovine serum albumin (BSA) in TBST (Tris
buffered saline containing 0.05% Tween 20) for 1 hour, before
probing with primary antibodies diluted in TBST containing 1%
non-fat milk for 1 hour, except for GAPDH where 1% BSA was
substituted for 1% non-fat milk. Membranes were then washed
thoroughly with TBST before incubating with appropriate horse
radish peroxidase-conjugated secondary antibodies (Pierce) for 1
hour at a 1:10,000 dilution. Membranes were again washed
thoroughly with TBST before bands were detected using Pierce
ECL Western blotting substrate in a dark room. Images were
initially exposed for 60 seconds, and further images produced
using longer or shorter exposure times depending on the intensity
of the bands in the initial image. Images were documented and
bands quantified using integrated optical density readings.
Statistical Analysis
All cell counts were produced from a minimum of 6 coverslips,
and Western blots from a minimum of 3 replicates. Cell counts
were performed using NIS Elements version 3 and statistical
interpretation performed using GraphPad version 5. Data plotted
on graphs is expressed as mean 6 SEM. Where more than two
conditions were compared ANOVA was followed by a Bonferroni
post-hoc test. Where two sets of data were compared a two tailed
unpaired t-test was performed. Results were considered statistically
significant for p values less than 0.05.
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